Ipsen and Exelixis announce phase 3 trial results of cabozantinib demonstrating significant overall survival benefit in patients with previously treated advanced hepatocellular carcinoma

Pivotal phase 3 CELESTIAL trial results, including additional subset analyses, to be presented during oral session on Friday, January 19 at the 2018 American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium (ASCO GI) In line with and in collaboration...